medigraphic.com
ISSN 0016-3813 (Print)

2008, Number 1

<< Back Next >>

Gac Med Mex 2008; 144 (1)

Recurrencia y supervivencia en cáncer mamario temprano con inmunofenotipo triple-negativo

Gerson R, Alban F, Villalobos A, Serrano A

Language: Spanish
References: 36
Page: 27-34
PDF size: 56.16 Kb.


ABSTRACT

Background: Axillary lymph node status, hormonal receptors (HR) and HER2 expression are significant prognostic factors for early breast cancer. Triple negative immunophenotype (HER2 and HR negative) is associated with a high frequency of recurrence and lower overall survival. The objective was assess clinical behavior, recurrence and survival of patients with triple negative early breast cancer and patients with other immunophenotypes.
Material and methods: We carried out a retrospective study among women with stages IIIB over 18 years with determination of HR and HER2 expression by immunohistochemical assay. We identified 5 groups: triple negative, triple positive, HER2 negative & HR positive, HER2 positive & HR negative, HER2 negative & 1 HR positive. We recorded age, date of diagnosis, clinical stage, tumor size, axillary lymph node status, ER, PR, HER2, p53, angiogenesis, Ki67, type of surgery, adjuvant treatment, time to recurrence, number and recurrence site and overall survival.
Results: 17 patients (15.4%) had triple negative phenotype, 14 (12.7%) triple positive, 52 (47.3%) were localized in group 3, 11(10%) in 4 and 16 (14.5%) in group 5. Triple negative phenotype was associated with increased cellular proliferation (p<0.000); being young (median 43 years), large tumor size (median size 2.5cm) lower proportion of patients in stage I and high frequency of p53 positive (78.5%). We observed a high frequency of recurrence and death among the triple negative group and among the HER2 positive and HR negative cases.
Conclusions: Triple negative breast cancer is more common among young women and is associated with a high frequency of recurrence and mortality. Clinical behavior among triple negative breast cancer cases is aggressive and displays a similar clinical profile that observed among HER2 positive and HR negative patients.


REFERENCES

  1. Globocan 2002. International Agency for Research on Cancer. Disponible en http://www.dep.iarc.fr

  2. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-616.

  3. Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials. Lancet 2005;365:1687-1717.

  4. Breast Cancer. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology V.2. 2007. Disponible en http://www.nccn.org

  5. Gerson R, Serrano A, Villalobos A, Sánchez-Forgach E, Sánchez-Basurto C, Murillo A, et al. Biomarcadores en el pronóstico y respuesta al tratamiento en cáncer mamario. Gac Med Mex 2002;138:15-24.

  6. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark R, Bowman D, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 years results from National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:549-471.

  7. Gerson R, Serrano A, Dolengevich H, Sánchez-Forgach E, Sánchez- Basurto C, Villalobos A, et al. c-erbB2 oncoprotein expression related to recurrence and survival in breast cancer patients. XXX World Congress of the International College of Surgeons; Kyoto, Japón. 1996.

  8. Ross JF, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-252.

  9. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006;13:236-248.

  10. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Nature 2000;96:9212-9217.

  11. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360.

  12. Kapp AV, Jeffrey SS, Langerod A, Borresen-Dale AL, Han Wonshik, Noh DY, et al. Discovery and validation of breast cancer subtypes. BMC Genomics 2006;7:231-244.

  13. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96-107.

  14. Sorlie T, Wang Y, Chunlin X, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analysis across three different platforms. BMC Genomics 2006;7:127-141.

  15. Valladares A, García-Hernández N, Salamanca-Gómez F, Curiel-Quezada E, Madrigal-Bujaidar E, Vergara MD, et al. Genetic expression profiles and chromosomal alterations in Mexican women. Cancer Genetics Cytogenetics 2006;170:147-151.

  16. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistocemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.

  17. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-244.

  18. Haffy BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-breast cancer. J Clin Oncol 2006;24:5652-5657.

  19. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.

  20. Bauer AR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population based study from the California cancer Registry. Cancer 2007;109:1721-1728.

  21. Altundag K, Harputluoglu H, Aksoy S, Gullu IH. Potential chemotherapy options in triple negative subtype of breast cancer. J Clin Oncol 2006;24:1294- 1295.

  22. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mol Pathol 2006;19:264-271.

  23. Kandel MJ, Stadler Z, Masciari S, Collins L, Schnitt S, Harris L, et al. Prevalence od BRCA-1 mutations in triple negative breast cancer. J Clin Oncol 2006;24(suppl 18):508.

  24. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Salmón DJ. The effect the HER2/neu over-expression on chemotherapeutic drugs sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-547.

  25. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 over expression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Willinston Park) 1997;11:43-48.

  26. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-2362.

  27. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006;8:66-77.

  28. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.

  29. Falo C, Moreno A, Varela M, Lloveras B, Figueras A, Escobedo A. HER-2/ neu status and response to CMF: restrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol 2007;133:423-429.

  30. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Desatininb, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-326.

  31. Leong CO, Vidnovic N, De Young MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-1380.

  32. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 2007;18:202-203.

  33. Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Alfred C, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.

  34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.

  35. Romond EW, Pérez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005;353:1673-1684.

  36. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive: a randomized controlled trial. Lancet 2007;369:29-36.




2020     |     www.medigraphic.com